FINWIRES · TerminalLIVE
FINWIRES

$RVTY

12 stories mentioning RVTYUpdated 3d ago

Every FINWIRES story that references RVTY, newest first.

What are analysts saying about RVTY?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on RVTY?

Equities

S&P 500 Posts Slight Weekly Decline as Utilities Weigh

The Standard & Poor's 500 index slipped 0.1% this week as the market digested a quarter-point rate increase from the Federal Reserve.The S&P 500 fell for a second straight week and ended Friday's session at 7,650.50. The market benchmark is down 0.5% for September but up 12% this year.The Fed's policy-setting committee on Wednesday raised its benchmark lending rate by 25 basis points in a unanimous vote to combat sticky inflation. The move lifted the federal funds rate to a range of 3.75% to 4%, the first time the Federal Open Market Committee has tightened monetary policy since July 2023.The Fed's Summary of Economic Projections showed the median policy rate at 4.1% by the end of 2026, up from 3.8% projected in June, signaling another rate increase later this year.The utilities sector had the largest percentage drop this week falling 3%, followed by a 2.35% fall in financials, a 2.3% decline in real estate and a 1.9% slip materials. Industrials, consumer discretionary, energy and consumer staples also moved lower.Constellation Energy (CEG) led the decline in utilities, falling 11% on the week. Last week, the company said it agreed to acquire RISEC Holdings, owner of the Rhode Island State Energy Center, from Shell's (SHEL) North America energy unit, for $715 million.Goldman Sachs (GS) was among the hardest-hit stocks in the financial sector, sliding 8.5%. Earlier this week, the company said its asset management alternatives unit raised $11.7 billion across its newest private equity funds and other vehicles.Nucor (NUE) was among the materials sector's decliners, falling 4.3%, as the steelmaker forecast Q3 earnings per share below analysts' mean estimate at the time. Nucor said its Q3 earnings "are expected to increase in the steel mills and steel products segments, while decreasing in the raw materials segment."Three sectors rose this week as health care climbed 1.8%, communication services gained 1.2% and technology was up 1.1%.Revvity (RVTY) led the gainers in health care, jumping 15% on the week. The company said it agreed to acquire Human Cell Design. The acquisition is expected to bolster Revvity's Life Sciences portfolio, including GLP-1 therapies, the companies said. Financial terms weren't disclosed.Meta Platforms (META) gave the communication services sector a boost, climbing 2.7% as the Facebook parent launched Meta One, a new subscription service offering enhanced AI capabilities and premium features across Instagram, Facebook, WhatsApp and Meta AI. Meta said the subscriptions are part of a broader effort to diversify revenue beyond digital advertising.Earnings reports next week are expected from companies including Costco Wholesale (COST), AutoZone (AZO), Darden Restaurants (DRI), Cintas (CTAS), Paychex (PAYX) and General Mills (GIS).Economic data will include the US Manufacturing Purchasing Managers' Index for September, as well as August new home sales and durable goods.

Dow JonesNasdaq CompositeS&P 500$CEG$GS$META$NUE$RVTY
Research

UBS Downgrades Revvity to Neutral From Buy, Adjusts Price Target to $140 From $120

Revvity (RVTY) has an average rating of overweight and mean price target of $127.29, according to analysts polled by FactSet.

$RVTY
Wire

Revvity Faces Growth Challenges Amid Rising Competition, RBC Says

Revvity's (RVTY) strong portfolio faces slowing growth and rising competition, raising questions about its ability to achieve its long-term growth outlook, RBC Capital Markets said in a note Tuesday.The company has built a strong portfolio across diagnostics and life sciences through years of acquisitions and divestments. However, growth at two of Revvity's key businesses, Euroimmun and BioLegend, has recently slowed, the analyst said.Euroimmun, which accounts for about 27% of sales, has slowed to mid- to high-single-digit growth. US sales grew more than 20% in Q2, but it is unclear if that pace will continue, and competition is expected to increase, the analyst added.The investment firm said Revvity's reagents business, which makes up about 26% of sales and is anchored by BioLegend, is growing at low-single-digit rates. It is also lagging the recovery in life science instrument demand and facing renewed competition.Overall, the company's long-term organic growth outlook of 6% to 8% faces structural challenges, according to the note.RBC initiated Revvity with a $135 price target and a sector perform rating.Price: $126.61, Change: $-2.06, Percent Change: -1.60%

$RVTY
Research

RBC Initiates Revvity at Sector Perform With $135 Price Target

Revvity (RVTY) has an average rating of overweight and mean price target of $123.50, according to analysts polled by FactSet.

$RVTY
Wire

Bernstein Adjusts Price Target on Revvity to $120 From $115, Maintains Market Perform Rating

Revvity (RVTY) has an average rating of overweight and mean price target of $121, according to analysts polled by FactSet.Price: $112.00, Change: $+0.61, Percent Change: +0.55%

$RVTY
Wire

TD Cowen Adjusts Price Target on Revvity to $130 From $120, Maintains Buy Rating

Revvity (RVTY) has an average rating of overweight and mean price target of $116.79, according to analysts polled by FactSet.Price: $111.77, Change: $+0.56, Percent Change: +0.50%

$RVTY
Wire

Baird Adjusts Price Target on Revvity to $128 From $117, Maintains Outperform Rating

Revvity (RVTY) has an average rating of overweight and mean price target of $116.07, according to analysts polled by FactSet.Price: $112.02, Change: $-0.28, Percent Change: -0.24%

$RVTY
Research

Research Alert: Rvty: Q1 Eps Beats Estimates, Announces China Immunodiagnostics Divestiture

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Revvity delivered solid Q1 2026 results with revenue rising 7% to $711M (1% above consensus) and adjusted EPS of $1.06, up 5% and beating consensus by 5%. Organic growth of 3% was supported by FX tailwinds of 3%-pts and acquisitions contributing 1%-pt despite persistent government and academia headwinds. We view positively the strategic decision to divest the China Immunodiagnostics business, representing ~6% of 2025 revenue, given recent policy headwinds from DRG reimbursement changes. Management provided 2026 guidance of $2.81B-$2.84B in sales and $5.20-$5.30 adjusted EPS, including 3%-4% organic growth, with the transaction expected to complete in 2027. Life Sciences grew 6% to $362M while Diagnostics showed stronger momentum at 8% growth to $349M, though both segments faced margin compression.

$RVTY
Wire

Baird Adjusts Revvity Price Target to $125 From $129, Maintains Outperform Rating

Revvity (RVTY) has an average rating of overweight and mean price target of $111.36, according to analysts polled by FactSet.Price: $87.24, Change: $+0.56, Percent Change: +0.65%

$RVTY
Research

Barclays Downgrades Revvity to Equalweight From Overweight, Adjusts Price Target to $95 From $118

Revvity (RVTY) has an average rating of overweight and mean price target of $113, according to analysts polled by FactSet.

$RVTY
Wire

TD Cowen Adjusts Price Target on Revvity to $115 From $124, Maintains Buy Rating

Revvity (RVTY) has an average rating of overweight and mean price target of $114.53, according to analysts polled by FactSet.Price: $90.26, Change: $+0.46, Percent Change: +0.52%

$RVTY
Wire

Goldman Sachs Adjusts Price Target on Revvity to $95 From $110, Maintains Neutral Rating

Revvity (RVTY) has an average rating of overweight and mean price target of $114.53, according to analysts polled by FactSet.Price: $90.26, Change: $+0.46, Percent Change: +0.52%

$RVTY

Track with the FINWIRES app suite